Tekmira Pharmaceuticals logo

TKM - Tekmira Pharmaceuticals Share Price

n/a 0.0  0.0%

Last Trade -

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £13.1m
Position in Universe th / 2677
Bullish
Bearish
Unlock TKM Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2008 2009 2010 2011 2012 2013 2014E 2015E CAGR / Avg
11.0 12.7 20.7 16.8 14.1 15.5 +7.1%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2014, ArbutusBiopharma Corp revenues increased 34% to $10.6M. Net lossincreased from $11.5M to $32.7M. Revenues reflect royaltypayments increase from $2K to $2.2M, Collaborations andcontracts increase of 6% to $8.4M. Higher net loss reflectsResearch, development and collaborations increase of 85% to$26.8M (expense), Increase in fair value of warrant liabilincrease from $2.2M to $12.9M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

TKM Revenue Unlock TKM Revenue

Net Income

TKM Net Income Unlock TKM Revenue

Normalised EPS

TKM Normalised EPS Unlock TKM Revenue

PE Ratio Range

TKM PE Ratio Range Unlock TKM Revenue

Dividend Yield Range

TKM Dividend Yield Range Unlock TKM Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
TKM EPS Forecasts Unlock TKM Revenue
Profile Summary

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing cure for people with chronic hepatitis B virus (HBV) infection. Its product pipeline is focused on finding curative combination regimen for chronic HBV infection, with the objective of developing a suite of products that intervene at different points in the viral life cycle and reactivate the host immune system. It is developing a product pipeline consisting of multiple drug candidates with complementary mechanisms of action. The Company’s HBV product pipeline includes ribonucleic acid (RNA) interference (RNAi) therapeutics, oral capsid inhibitors, oral compounds that inhibit programmed death-ligand one (PDL1) and oral HBV RNA destabilizers. Its subsidiaries include Arbutus Inc and Arbutus Biopharma US Holdings, Inc.

Directors
Last Annual December 31st, 2013
Last Interim September 30th, 2014
Incorporated January 1, 2018
Public Since November 13, 2010
No. of Shareholders: n/a
No. of Employees: 85
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange Toronto Stock Exchange
Shares in Issue 84,909,258
Free Float (0.0%)
Eligible for
ISAs
SIPPs
TKM Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for TKM
Upcoming Events for TKM
Frequently Asked Questions for Tekmira Pharmaceuticals
What is the Tekmira Pharmaceuticals share price?

As of , shares in Tekmira Pharmaceuticals are trading at n/a, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the Tekmira Pharmaceuticals share price performed this year?

Shares in Tekmira Pharmaceuticals are currently trading at n/a and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Tekmira Pharmaceuticals price has moved by % over the past year.

What are the analyst and broker recommendations for Tekmira Pharmaceuticals?

There are no analysts currently covering Tekmira Pharmaceuticals.

When will Tekmira Pharmaceuticals next release its financial results?

Tekmira Pharmaceuticals is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2015-09-30
What is the Tekmira Pharmaceuticals dividend yield?

Tekmira Pharmaceuticals does not currently pay a dividend.

Does Tekmira Pharmaceuticals pay a dividend?

Tekmira Pharmaceuticals does not currently pay a dividend.

When does Tekmira Pharmaceuticals next pay dividends?

Tekmira Pharmaceuticals does not currently pay a dividend.

How do I buy Tekmira Pharmaceuticals shares?

To buy shares in Tekmira Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Tekmira Pharmaceuticals?

Shares in Tekmira Pharmaceuticals are currently trading at n/a, giving the company a market capitalisation of £n/a.

Where are Tekmira Pharmaceuticals shares listed? Where are Tekmira Pharmaceuticals shares listed?

Here are the trading details for Tekmira Pharmaceuticals:

Country of listing: Canada
Exchange: TOR
Ticker Symbol: TKM
What kind of share is Tekmira Pharmaceuticals?

We were not able to load our ranking data for Tekmira Pharmaceuticals

Is there a Tekmira Pharmaceuticals share price forecast 2021?

We were not able to load any forecast data for Tekmira Pharmaceuticals.

How can I tell whether the Tekmira Pharmaceuticals share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Tekmira Pharmaceuticals. Over the past six months, the relative strength of its shares against the market has been %. At the current price of n/a, shares in Tekmira Pharmaceuticals are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Tekmira Pharmaceuticals PE Ratio?

We were not able to find PE ratio data for Tekmira Pharmaceuticals.

Who are the key directors of Tekmira Pharmaceuticals?

We were unable to find the directors for Tekmira Pharmaceuticals.

Who are the major shareholders of Tekmira Pharmaceuticals?

Here are the top five shareholders of Tekmira Pharmaceuticals based on the size of their shareholding:

Similar to TKM
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.